Analyst Price Targets — IRMD
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 11, 2026 1:44 pm | — | Lake Street | $120.00 | $106.02 | TheFly | iRadimed price target raised to $120 from $100 at Lake Street |
| February 10, 2026 8:36 pm | — | Roth Capital | $120.00 | $105.15 | TheFly | iRadimed price target raised to $120 from $98 at Roth Capital |
| November 3, 2025 8:10 pm | Kyle Bauser | Roth Capital | $98.00 | $84.11 | TheFly | iRadimed price target raised to $98 from $90 at Roth Capital |
| November 3, 2025 6:28 pm | — | Lake Street | $100.00 | $84.11 | TheFly | iRadimed price target raised to $100 from $75 at Lake Street |
| October 31, 2025 8:24 am | Kyle Bauser | Roth Capital | $90.00 | $76.42 | TheFly | iRadimed resumed with a Buy at Roth Capital |
| August 2, 2024 8:40 am | Jason Wittes | Roth Capital | $60.00 | $46.15 | TheFly | iRadimed price target lowered to $60 from $65 at Roth MKM |
| June 17, 2024 9:49 am | Frank Takkinen | Loop Capital Markets | $60.00 | $43.29 | StreetInsider | Lake Street Capital Markets Reiterates Buy Rating on IRadimed Corp (IRMD) |
Latest News for IRMD
Principal Financial Group Inc. bought a new position in iRadimed Corporation (NASDAQ: IRMD) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 5,927 shares of the medical equipment provider's stock, valued at approximately $422,000. Several other hedge funds have also modified their
Nine Ten Capital Management sold 342,907 shares of IRadimed; the estimated transaction value was $29.42 million based on quarterly average price. The quarter-end position value decreased by $13.21 million, reflecting both share sales and price changes.
For the 18th time in a row, the niche medical device maker set a new all-time high for quarterly revenue. It also handily topped the consensus analyst estimate for adjusted net profit.
IRADIMED CORPORATION (IRMD) Q4 2025 Earnings Call Transcript
ORLANDO, Fla., Feb. 10, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company” or “Iradimed”) (NASDAQ: IRMD) announced today its financial results for the quarter and year ended December 31, 2025. The Company is a leader in developing innovative magnetic resonance imaging (“MRI”) compatible medical devices and products. The Company is a provider of (i) non-magnetic intravenous (“IV”) infusion pump systems and…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for IRMD.
U.S. House Trading
No House trades found for IRMD.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.